A 12-week, Double-blind, International, Multicenter, Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Latest Information Update: 01 Oct 2020
At a glance
- Drugs Beraprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Lung Rx
- 17 Jun 2014 New trial record